Figure 4 The gut–liver relationship in PSC

Slides:

Advertisements

Similar presentations

Primary Sclerosing Cholangitis

Advertisements

Autoimmunity and Type I Diabetes CCMD 793A: Fundamental Integrated SystemsFALL, 2006 James M. Sheil, Ph.D.

DIGESTIVE SYSTEM the gastrointestinal tract (GI tract), digestive tract, guts or gut is the system of organs within multicellular organisms that takes.

Introduction to PSC: From A to Z

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Orthotopic liver transplant, recurrent primary sclerosing cholangitis

Basics of PSC Christopher L. Bowlus, MD

Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 3 Neutrophils in liver inflammation

Figure 5 Dendritic cells in liver inflammation

Figure 1 Contribution of the gut microbiota

Update on primary sclerosing cholangitis

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 5 Lipid droplet consumption

Figure 2 The microbiome–gut–brain axis

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immune mechanisms in liver homeostasis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 3 The 'leaky gut' hypothesis

Gallstone Disease and Cancer Risk: Finding the Bug in the System

Figure 4 Giant lipid droplet formation

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Gut–liver immunity Journal of Hepatology

Figure 5 Intestinal lymph draining pattern and contents

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Genetics of liver disease: From pathophysiology to clinical practice

Targeting the gut-liver axis in liver disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

Figure 3 Serotonin influences many peripheral tissues

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Cross-sectional integrated brain–gut model of IBS pathophysiology

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Inflammatory Bowel Disease Is Associated With Poor Outcomes of Patients With Primary Sclerosing Cholangitis Jing Hieng Ngu, Richard Blair Gearry, Andrew.

Bridging immunity and lipid metabolism by gut microbiota

Figure 2 Microbiota-related pathways in atherosclerosis

Microbes, Microbiota, and Colon Cancer

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 4 The gut–liver relationship in PSC Figure 4 | The gut–liver relationship in PSC. Primary sclerosing cholangitis (PSC) shows a strong clinical association with IBD. The relationship between the concomitant bile duct and bowel affection is not clear, although most hypotheses involve a disturbance of the bowel as the primary affection. In anatomical terms, the disease distribution of PSC follows that of the enterohepatic and cholehepatic circulation of bile acids (terminal ileum, proximal colon, bile ducts). Multiple interactions exist between the gut and the liver throughout this anatomical compartment, for both immunological and metabolic functions. Gut-derived nutrients and other signals, including primary and secondary bile acids, drugs and other xenobiotics, microbial products and antigenic components, are delivered to the liver via the portal circulation. These interactions have led to a series of hypotheses on PSC development which include the homing of gut-derived lymphocytes to the portal areas75, leakage of LPS and other bacterial components into the portal circulation125, and the possible presence of an antigenic trigger derived from the colonic content251. Building from genetic studies, adaptive immune reactions occurring throughout this bidirectional gut–liver axis probably occur, but the specific factor(s) driving these reactions remain to be determined. Jiang, X. & Karlsen, T. H. (2017) Genetics of primary sclerosing cholangitis and pathophysiological implications Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.154